Study Group: Radiation Oncologists (EU)(?)

As a memebr of the START Trial group I can confirm that over the period of this study follow up (5 years) in many thousands of patients the recurrence rate following lumpectomy for early breast cancer and only 3 weeks of radiotherapy was the same as that for 5 weeks and very low (approx 3-4%). The 3...

Essentially we are moving into an arena where cancer drugs will be more and more specific to individual groups of patients with cancer. For example in breast cancer all patients used to be treated the same. Now patients with tumours that are ER positive are given hormonal therapies and not those with...

There were certain unresolved issues before the clinical usage of fentanyl in cancer patients. There are interesting metabolic features of this potent drug. First of all, its LD50 (the dosage causing the %50 death to applied laboratory animals) value is 100 times lower in primates than rodents (mice,...

Differentiation-inducing liposoluble vitamins are being used for about 20 years in hematological oncology, after the finding that all-trans-retinoic acid (ATRA) differentiates promyelocytic leukemia clones leading clinical benefits. With this discovery, interest into retinoids (Vitamin A derivatives)...